Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Cash from Financing Activities: 2022-2024

Historic Cash from Financing Activities for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to $29.2 million.

  • Orchestra BioMed Holdings' Cash from Financing Activities rose 408.13% to $76.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $89.6 million, marking a year-over-year increase of 1879.24%. This contributed to the annual value of $29.2 million for FY2024, which is 36.88% down from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Cash from Financing Activities of $29.2 million as of FY2024, which was down 36.88% from $46.2 million recorded in FY2023.
  • Orchestra BioMed Holdings' 5-year Cash from Financing Activities high stood at $103.3 million for FY2022, and its period low was $29.2 million during FY2024.
  • For the 3-year period, Orchestra BioMed Holdings' Cash from Financing Activities averaged around $59.5 million, with its median value being $46.2 million (2023).
  • Data for Orchestra BioMed Holdings' Cash from Financing Activities shows a maximum YoY plummeted of 55.24% (in 2023) over the last 5 years.
  • Over the past 3 years, Orchestra BioMed Holdings' Cash from Financing Activities (Yearly) stood at $103.3 million in 2022, then tumbled by 55.24% to $46.2 million in 2023, then tumbled by 36.88% to $29.2 million in 2024.